News

Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. 

Recorded webcast now available

Evotec SE announced today that, as part of its ongoing collaboration with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, STORM has selected STC-15 as a first-in-class development candidate. STORM will now use INDiGO, Evotec’s unique integrated, accelerated IND-enabling platform, to progress STC-15 towards an IND application in 2021.

MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE; INCREASING MOMENTUM DESPITE DIFFICULT BUSINESS ENVIRONMENT; GUIDANCE FOR FULL-YEAR 2020 CONFIRMED; CAPACITY EXPANSION ON TRACK FOR SWIFT START TO 2021

Evotec SE today announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for cutting-edge and high-performance small molecule discovery and up to commercial development.

Evotec SE will announce its financial results for the first nine months of 2020 on Thursday, 12 November 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English

Evotec SE announced today that its management will be presenting at and attending upcoming conferences until the end of 2020.

Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis ("NASH") to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team.

Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.

Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round.

Evotec SE today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by € 250 million in total.

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project.

Evotec SE and the French-based BIOASTER Technological Research Institute today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy.

Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft making it one of the largest occupiers on the Park.

Evotec SE today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (“QUOD”), an initiative of The Nuffield Department of Surgical Sciences (“NDS”) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (“NHSBT”) organisation in the UK.

Evotec SE and CENTOGENE N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the companies have expanded their existing drug discovery partnership related to the protein target glucocerebrosidase (“GBA”) with a focus on Gaucher disease, a genetic and relatively common lysosomal storage disorder. The parties intend to develop a treatment option for the majority of patients whereas currently available treatments are individualised for each patient depending on the type of Gaucher disease, focusing on symptomatic relief.

Evotec SE and Novo Nordisk today announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients. The collaboration intends to pursue the most relevant human disease biology in a therapeutic modality-agnostic approach to develop first-in-class therapeutics for patients suffering from CKD.

Evotec SE today announced its financial results for the first half-year of 2020: Significant Group revenue growth of 12% to € 231.0 m (H1 2019: € 207.1 m); Revenue growth in both business segments: EVT Execute revenues up 16% to € 228.2 m (H1 2019: € 196.8 m); EVT Innovate revenues up 8% to € 44.6 m (H1 2019: € 41.2 m); Adjusted Group EBITDA amounting to € 47.3 m (H1 2019: € 58.2 m)

Evotec SE announced today that the Company has entered into a new partnership with the Biotech company Resolute Therapeutics (“Resolute”) to combat infectious diseases and antimicrobial resistance. The partnership aims to develop a broad-spectrum antibiotic with a new mode of action compared to antibiotics currently on the market and will receive substantial funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership led by Boston University and dedicated to funding and supporting the development of therapeutics, vaccines and rapid diagnostics to address the most serious drug-resistant bacteria.

Evotec SE and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), today announced a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. 

Evotec SE will report its financial results for the first half-year of 2020 on Wednesday, 12 August 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020. The conference call will be held in English.

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD.

Evotec SE announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH (“QUANTRO”), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.

Evotec SE today announced that Evotec has added significant opportunity for further, long-term growth of its Toulouse-based operations by taking over “Biopark by Sanofi”.

 The 9th edition of DDup is dedicated to our unique and innovative iPSC-based drug discovery programme TargetRD (Retinal Disease), which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden.

Evotec SE, Samsara BioCapital, a leading life sciences investment firm, and KCK Ltd., a family investment fund, today announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. 

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2020 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting was held as a purely virtual event. 

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

Evotec SE today announced that its wholly owned subsidiary Cyprotex US, LLC has been awarded a new 5 year contract with the US Environmental Protection Agency (“EPA”). The project forms part of the EPA’s Computational Toxicology and Exposure Research efforts (“CompTox”) whose goal is to provide solutions-driven research to rapidly evaluate the potential human health and environmental risks due to exposures to environmental chemicals. 

Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues during this challenging time.

Evotec SE today announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence (“AI”)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the round.

Evotec SE today announced the financial results and corporate updates for the first quarter 2020. 15% increase in group revenues from contracts with customers to € 119.4 m; Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m); Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m); No material impact by COVID-19 pandemic on financial development so far 

Evotec SE and its collaborators Toronto Innovation Acceleration Partners (“TIAP”) and AmorChem Therapeutics today announced a $ 1.75 m investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.

Evotec SE will report its financial results for the first quarter of 2020 on Thursday, 14 May 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020.

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (“Ology Bio”) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.

Evotec SE announced today that it will regain global development and commercialisation rights to the iPSC-based programme for the treatment of diabetes developed under collaboration agreement with Sanofi. 

Evotec SE today announced a strategic partnership and equity investment with leon-nanodrugs GmbH (“leon”). Based in Munich, Germany, leon is the leading enabler of nanotechnology for the pharmaceutical industry. Under the terms of the agreement, Evotec and leon will cooperate on selected development programmes and maximise the effectiveness of clinical and commercial nanomedicines.

Just – Evotec Biologics announced today that the Company has compiled a library of a new class of humanoid antibodies using a novel, AI-derived approach. Antibodies are proteins produced and secreted by B-cells. As they bind to foreign substances that invade the body, such as pathogens and a plethora of other targets, they represent an important class of biologics-based therapeutics.

Evotec SE today announced that the Company has established a dedicated site for research and development of gene therapy-based projects: Evotec Gene Therapy (“Evotec GT”) which will start operations with a strong team of gene therapy experts at an R&D site in Orth/Donau, Austria.

Evotec SE today announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Evotec GT is an integral part of Evotec’s integrated fully modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain. 

Evotec SE and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”, which are genetically modified to prevent immune rejection of derived cell therapy products (“cloaking”). 

Evotec SE announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform.

Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2019. Group revenues up 19% to € 446.4 m, adjusted Group EBITDA up 29% to € 123.1 m, unpartnered R&D expenses of € 37.5 m, liquidity position more than doubled to € 320.0 m.

Evotec’s partner Forge Therapeutics, Inc. (“Forge”) today announced a research collaboration and option agreement with Hoffmann-La Roche Ltd. (“Roche”) to license one of its novel antibiotics for the treatment of hospital-based lung infections. The targeted infections includes those cited on the CDC’s most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases.

Evotec SE will report its financial results for 2019 on Thursday, 26 March 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2020.

Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment.

The exact number of women suffering from endometriosis is unknown. However, it is estimated that 10% of women worldwide are affected. Endometriosis is a debilitating disease in which the endometrial cells that usually line the uterus are found in other regions of the body.

Evotec SE announced today that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.

Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”).

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology.

Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality.

Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.

Evotec SE announced today that its management will be presenting at and attending investor conferences in January and February 2020.

Evotec SE today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S.

Evotec SE today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.